Abstract 1849: Identification and functional analysis of SHISA2 overexpressed in prostate cancer

Abstract Prostate cancer (PC) is usually androgen-dependent and responds well to androgen ablation therapy. However, at a certain stage some prostate cancers eventually acquire a castration-resistant phenotype. These cancer cells are originally high-grade and show very poor response to any anticance...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 72; no. 8_Supplement; p. 1849
Main Authors Tamura, Kenji, Furihata, Mutsuo, Satake, Hirofumi, Anchi, Takashi, Kamei, Maiko, Fukuhara, Hideo, Shimamoto, Tsutomu, Ashida, Shingo, Karashima, Takashi, Yamasaki, Ichiro, Nishikawa, Hiroshi, Kamada, Masayuki, Yasuda, Masaharu, Inoue, Keiji, Shuin, Taro
Format Journal Article
LanguageEnglish
Published 15.04.2012
Online AccessGet full text

Cover

More Information
Summary:Abstract Prostate cancer (PC) is usually androgen-dependent and responds well to androgen ablation therapy. However, at a certain stage some prostate cancers eventually acquire a castration-resistant phenotype. These cancer cells are originally high-grade and show very poor response to any anticancer therapies. To identify novel molecular cancer drug targets, we previously analyzed the gene expression profiles of high-grade PCs using a cDNA microarray combined with laser microbeam microdissection and found a number of genes that are transactivated in high-grade PC. Among them, we report the identification of a novel molecular target, SHISA2. We confirmed overexpression of SHISA2 in high-grade prostate cancer cells by semi-quantitative RT-PCR and immunohistochemical analysis. Knockdown of SHISA2 expression by siRNA in a prostate cancer cell line resulted in a drastic decrease of cell numbers. In contrast, SHISA2 overexpression in a prostate cancer cell line promoted cell proliferation. These findings suggest that SHISA2 could be involved in aggressive phenotype of prostate cancers, including castration-resistant prostate cancers, and that it should be a potential molecular target for development of new therapeutics and a diagnostic biomarker for aggressive prostate cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1849. doi:1538-7445.AM2012-1849
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2012-1849